# Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients

Study · id `cardio:ct-nct05914857` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05914857](<https://clinicaltrials.gov/study/NCT05914857>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05914857

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT05914857. Randomized; single masking; primary purpose treatment. Start 2023-12-20 (anticipated); primary completion 2025-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT05914857, source copy `cardio:ctgov-nct05914857-2023-07-25`, retrieved 2026-11-18)
- Planned start: 2023-12-20 (anticipated) (ClinicalTrials.gov record NCT05914857, source copy `cardio:ctgov-nct05914857-2023-07-25`, retrieved 2026-11-18)
- Primary completion: 2025-06-01 (anticipated) (ClinicalTrials.gov record NCT05914857, source copy `cardio:ctgov-nct05914857-2023-07-25`, retrieved 2026-11-18)
- Completion: 2025-12-01 (anticipated) (ClinicalTrials.gov record NCT05914857, source copy `cardio:ctgov-nct05914857-2023-07-25`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT05914857, source copy `cardio:ctgov-nct05914857-2023-07-25`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05914857-2023-07-25`, retrieved 2026-11-18)

## The registry's words

- Brief title: Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients
- Condition: Prediabetic State
- Condition: Impaired Fasting Glucose
- Condition: Impaired Glucose Tolerance
- Intervention (Drug): Dapagliflozin 10mg Tab
- Intervention (Behavioral): lifestyle interventions
- Lead sponsor: Yangjin
- Lead sponsor class: OTHER
- Collaborator: Peking University Third Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry lists this organization as a collaborator: Peking University Third Hospital (`cardio:org-peking-university-third-hospital`)

## Provenance

Content hash: 22e61c0df8e36f25d6f944e98dbe19404cafd0047f1f1dcfaac5fd70894655f5
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
